Journey Medical Corporation announced that the FDA has accepted the Company's New Drug Application (NDA) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.9 USD | +2.63% | +8.33% | -32.29% |
May. 13 | Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024 | |
May. 13 | Journey Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.29% | 78.05M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- DERM Stock
- News Journey Medical Corporation
- Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea